Abbvie Inc
NYSE:ABBV
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
137.6
191.23
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
Abbvie Inc
NYSE:ABBV
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Realty Income Corp
NYSE:O
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Abbvie Inc
Wall Street
Price Targets
ABBV Price Targets Summary
Abbvie Inc
According to Wall Street analysts, the average 1-year price target for
ABBV
is 199.76 USD
with a low forecast of 171.7 USD and a high forecast of 225.75 USD.
ABBV Last Price Targets
Abbvie Inc
The latest public price target was made on Jul 19, 2024 by
Evan Seigerman
from
BMO Capital
,
who expects
ABBV
stock to
rise by 12%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Evan Seigerman
BMO Capital
|
214
USD
Upside 12% |
3 weeks ago
Jul 19, 2024
|
AbbVie price target raised to $214 from $180 at BMO Capital
TheFly
|
Christopher Raymond
Raymond James
|
190
USD
Downside 1% |
1 month ago
Jun 18, 2024
|
Abbvie (ABBV) PT Raised to $190 at Piper Sandler
StreetInsider
|
Rajesh Kumar
HSBC
|
185
USD
Downside 3% |
2 months ago
Jun 5, 2024
|
HSBC Upgrades Abbvie (ABBV) to Buy
StreetInsider
|
James Shin
Deutsche Bank
|
175
USD
Downside 8% |
2 months ago
May 24, 2024
|
Deutsche Bank Reiterates Hold Rating on Abbvie (ABBV)
StreetInsider
|
|
Louise Chen
Cantor Fitzgerald
|
200
USD
Upside 5% |
2 months ago
May 17, 2024
|
Cantor Fitzgerald Starts Abbvie (ABBV) at Overweight
StreetInsider
|
|
Evan Seigerman
BMO Capital
|
180
USD
Downside 6% |
3 months ago
Apr 29, 2024
|
AbbVie price target lowered to $180 from $195 at BMO Capital
TheFly
|
Carter Gould
Barclays
|
195
USD
Upside 2% |
4 months ago
Mar 27, 2024
|
Abbvie (ABBV) PT Raised to $195 at Barclays
StreetInsider
|
|
Christopher Raymond
Raymond James
|
170
USD
Downside 11% |
9 months ago
Nov 9, 2023
|
Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts
Benzinga
|
|
Gary Nachman
Raymond James
|
177
USD
Downside 7% |
10 months ago
Sep 29, 2023
|
AbbVie's Promising Leap Towards Long-Term Growth: Analyst
Benzinga
|
Vamil Divan
Guggenheim
|
171
USD
Downside 11% |
1 year ago
May 9, 2023
|
Check Out 3 Health Care Stocks With Over 3% Dividend Yields From Wall Street's Most Accurate Analysts
Benzinga
|
|
Unknown Analyst
BMO Capital
|
167
USD
Downside 13% |
1 year ago
Feb 6, 2023
|
BMO Capital Maintains Outperform on AbbVie, Lowers Price Target to $167
Benzinga
|
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is ABBV's stock price target?
Price Target
199.76
USD
According to Wall Street analysts, the average 1-year price target for
ABBV
is 199.76 USD
with a low forecast of 171.7 USD and a high forecast of 225.75 USD.
What is Abbvie Inc's Revenue forecast?
Projected CAGR
6%
For the last 8 years the
compound annual growth rate for
Abbvie Inc's revenue is
11%.
The projected
CAGR
for the next 3 years is
6%.
What is Abbvie Inc's Operating Income forecast?
Projected CAGR
23%
For the last 8 years the
compound annual growth rate for
Abbvie Inc's operating income is
10%.
The projected
CAGR
for the next 3 years is
23%.
What is Abbvie Inc's Net Income forecast?
Projected CAGR
72%
For the last 8 years the
compound annual growth rate for
Abbvie Inc's net income is
-1%.
The projected
CAGR
for the next 3 years is
72%.
You don't have any saved screeners yet
